PTIX News and Press, Protagenic Therapeutics Inc. From 05/01/24

NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating n...

2024-04-23 13:16:54 ET More on Mid-day movers & stocks. Kopin Corporation (KOPN) Q4 2023 Earnings Call Transcript Cemtrex, Inc. (CETX) Q1 2024 Earnings Call Transcript Kopin GAAP EPS of -$0.06 misses by $0.03, revenue of $8.6M misses by $0.43M Cemtrex GAA...

Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a tal...

2024-04-01 21:32:08 ET Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Conference Call April 1, 2024 04:30 PM ET Company Participants Alex Arrow - CFO Garo Armen - Executive Chairman Andrew Slee - COO Bob Stein - CMO Conference Call Participants ...

2024-04-01 16:30:19 ET More on Protagenic Therapeutics Financial information for Protagenic Therapeutics Read the full article on Seeking Alpha For further details see: Protagenic Therapeutics GAAP EPS of -$1.15

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final tw...

Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The ...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Call Scheduled for Monday, April 1 st , 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in i...

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This re...